The API is supplied as a crystalline powder and is controlled under a CEP or ASMF; the certificate of analysis covers residual solvents by USP <467> and elemental impurities by USP <232>/<233>. In direct compression lines for low-dose SGLT2 inhibitor salts, the sequence of blending and lubrication often becomes the primary source of content uniformity drift. The L-proline salt is received with defined bulk density, tapped density, and flow function; these are checked against the API specification before the dry blend is assembled. If the particle size distribution contains a D₉₀ above 250 µm, the API is first passed through a cone mill fitted with a 0.5 mm or 0.8 mm screen. Milled material is pre-blended with a directly compressible filler and disintegrant in a 30 L bin blender at a fill ratio not exceeding 70% of vessel volume. The pre-blend is sampled after a defined number of revolutions, and blend uniformity is assessed by a validated near-infrared or HPLC method under ICH Q2(R1) conditions.

Lubricant addition is a separate step because over-lubrication of the L-proline salt can reduce tablet tensile strength. Magnesium stearate is screened at 0.5–1.0% w/w and mixed for a terminal blending time that is intentionally short. Routine ejection force and tablet hardness data confirm the endpoint. Compression is performed on an instrumented rotary press with 8 mm round concave tooling; precompression is typically set between 4 kN and 8 kN, and main compression between 8 kN and 16 kN, depending on tablet weight and required hardness. Tablet breaking force is monitored per USP <1217>, and friability is checked per USP <1216>. In production runs, a recurring failure mode occurs when relative humidity exceeds 60% RH; punch filming and increased ejection force are observed, requiring a humidity-controlled compression suite or pre-drying of the blend.

The release specification for an immediate-release tablet includes content uniformity by USP <905>, dissolution by USP <711>, disintegration by USP <701>, and water content by USP <921>. Dissolution media for comparison are generally selected from 0.1 N HCl, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer; the discriminating medium is defined by the pH-solubility profile of the salt. If the direct compression route shows dissolution slowing at late time points, the formulation is adjusted through disintegrant ratio and filler type rather than through particle size reduction alone. The batch record defines the salt-to-base correction factor and the exact lubrication interval, because these two variables directly affect label claim and content uniformity.

What Process Windows Govern a Wet Granulation Line for Ipragliflozin L-Proline Tablets?

Wet granulation is selected when the direct compression blend segregates during transfer or when the target drug load is below 1.0% w/w and dose uniformity cannot be sustained with dry blending alone. A high-shear granulator equipped with impeller and chopper is charged with the API pre-mix; binder solution is added by peristaltic pump under impeller power and torque control. The granulation endpoint is determined by the power consumption plateau rather than by a fixed time, because batch-to-batch variation in particle size and surface moisture shifts the liquid demand. Endpoint over-granulation increases the mean granule size and produces hard dry granules that later resist compression and slow dissolution.

After wet granulation, the granulate is dried in a fluid bed dryer with inlet air temperature between 55 °C and 70 °C and product temperature maintained between 30 °C and 40 °C. Loss on drying is tested by USP <731>; the registered endpoint is typically set as a narrow range, and the dryer airflow and dew point are recorded as critical process parameters. Dried granules are milled through a 1.0 mm screen, blended with extragranular disintegrant and lubricant, and compressed on the same rotary press. The wet granulation route is particularly sensitive to residual moisture: granules below the endpoint may generate fines during milling, while granules above the endpoint may exhibit picking and sticking during compression.

Process characterization for this route is performed using a design of experiments that varies binder concentration, water addition, and drying endpoint. Responses are granule size distribution at D₁₀, D₅₀, and D₉₀, tablet hardness, disintegration time, and dissolution at 15 min. The control strategy includes in-process checks for bulk density, tapped density, and moisture, and the dissolution method remains USP <711> with a validated HPLC analysis. If the tablet shows content uniformity failure at the start of the compression run, the usual root cause is inadequate pre-mixing of the low-dose API with the filler prior to granulation; corrective action is a longer pre-mix or a geometric dilution of the API.

When capsule filling is selected for the same API, fill weight control and shell moisture transfer replace compression profile as the critical process parameters. The low-dose powder blend or granulation is filled into hard gelatin or HPMC capsules by either dosator or tamping-pin equipment. The powder bed height and particle size distribution of the lubricated blend influence fill weight variation. Fill weight is checked at defined intervals by in-process weight sorting; the acceptance criteria are tied to the weight variation procedure in USP <905>. Capsule shells with residual moisture below 3% w/w are preferred; higher shell moisture can transfer to the API and promote sticking or degradation.

Because ipragliflozin L-proline can be sensitive to moisture, the capsule fill is specified for water content by USP <921>; desiccant loading in packaging is based on the equilibrium moisture sorption isotherm. Blend flow is measured by USP <1174>; if the compressibility index exceeds 25%, the blend is granulated before filling to prevent rat-holing and weight drift. Capsule dissolution testing is performed by USP <711>, and the dissolution profile from capsules is compared with the tablet profile in the same media. For enteric or delayed-release development, the capsule contents would require a functional coating or enteric capsule shell; published data for this specific configuration is limited, so early feasibility work should confirm gastric resistance and intestinal release.

If Sachet Granules Are Required, Particle Size Distribution Determines Dose Uniformity and Dispersion

When the product is presented as oral granules in single-dose sachets, the batch is judged first by its particle size distribution and only then by compaction performance. Granules are milled to a target range that avoids both large hard granules and fine powder below 75 µm, because ultrafines segregate during sachet filling and create dust. A shaker-sieving method based on USP <786> is used to monitor particle size distribution at release and during stability. The granule surface area affects dispersion time; wider particle size distribution increases the probability of dose variation among sachets.

Dose uniformity for sachets is evaluated by USP <905> applied to the filled granule mass; fill weight is controlled by a vertical form-fill-seal machine with auger or volumetric cup feed. The granule moisture content is limited by USP <921> because wet granules agglomerate in the dosing cup. The finished sachet is tested for seal integrity by vacuum decay or dye penetration, and the package includes a desiccant when moisture uptake data show an increase above 0.5% water content over the shelf-life condition. Dispersion time in water is recorded as an in-house test; the material should disperse readily without forming a non-wetted raft.

Dissolution of granules is performed by USP <711> on the individual sachet contents; the stirring speed and deaeration are standardized because the granule surfaces contain fine API and can float. The analytical method must account for the L-proline counterion; label claim is expressed as the free base equivalent, and the salt factor is defined in the certificate of analysis. Process capability for sachet fill weight is monitored with ±5% target fill weight limits, and in-process sampling frequency is increased when the granule size distribution shifts more than 10% from the pivotal batch.

For fixed-dose combination tablets with metformin hydrochloride, the formulation problem shifts to compaction of a high-dose, poorly compressible counterion while protecting a low-dose ipragliflozin component. Metformin hydrochloride is usually difficult to compress; it may require a roller compaction step or a high-shear granulation step before final blending. Ipragliflozin L-proline is pre-blended with a portion of filler and then added to the metformin granulation to avoid adhesion and content uniformity loss. The two APIs are monitored by a single HPLC method capable of resolving both actives; system suitability is defined under ICH Q2(R1).

Bilayer tablet compression is used when the immediate-release profiles of the two actives require different disintegrant systems or when chemical interaction is observed during stability. The first layer is compressed at low force, and the second layer is added at final compression; layer separation at the interface remains the main failure mode on a production press. Tablet hardness is checked by USP <1217>, and the finished tablet is film-coated with a moisture-protective coating at a weight gain of 2–4% w/w. The coating pan inlet air temperature and spray rate are controlled to avoid over-wetting the metformin layer, which can cause surface erosion and weight gain variability.

Dissolution testing for the fixed-dose combination is performed by USP <711> using separate detection wavelengths for metformin and ipragliflozin. The metformin component is usually tested at a wavelength where ipragliflozin does not interfere; the selected medium and rotation speed are justified by a discriminatory power study. If the low-dose component fails content uniformity in the finished tablet, the root cause is usually segregation in the feed frame or an incorrect granule size ratio between the two APIs; a staged blending sequence with pre-blending of the low-dose API is the standard corrective measure. Published data for this specific fixed-dose combination configuration is limited; therefore the development batch record includes additional stratified sampling and force-displacement data.

Injectable Solution pH, Oxygen, and Terminal Sterilization Are Evaluated as a Single System

The injectable presentation begins with dissolving the L-proline salt in Water for Injection in a stainless steel or disposable compounding vessel. The solution is purged with pharmaceutical-grade nitrogen before pH adjustment, because oxygen can accelerate oxidative degradation of the active molecule. pH is adjusted with dilute hydrochloric acid or sodium hydroxide under a pH meter calibrated per USP <791>; the target pH is derived from forced degradation screening and solubility data. If buffer capacity is required, phosphate or citrate buffers are screened for buffering capacity and pain-on-injection data, but the final choice must avoid divalent cations that can precipitate the salt.

The solution is filtered through a 0.22 µm sterilizing-grade membrane that has been qualified for compatibility and extractables per USP <1663> and USP <1664>. Filter integrity is tested before and after filtration by bubble point, diffusion, or water intrusion per the filter manufacturer's technical bulletin. The filtered solution is filled into glass vials or pre-sterilized syringes in an aseptic processing line under EU GMP Annex 1 conditions; the closure system is selected by USP <660> glass evaluation and elastomeric closure functionality.

If terminal sterilization is feasible, a moist heat overkill cycle at 121.1 °C for 15 min is evaluated first, but the cycle is only acceptable if related substances remain within specification and assay stays within label claim. If the molecule is heat-labile, aseptic filtration is used and every batch requires environmental monitoring data and media fill evidence. The finished injectable is tested for sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, osmolality by USP <785>, and visible particles by USP <790>. The particulate matter method uses light obscuration; samples are de-aerated to avoid false counts from gas bubbles.